Clinical TrialsMedicare | Clinical TrialsPrivate Insurance | Medicare Payment FDA | Cancer Research | Stem Cell Research | Privacy | Other |
||||
CLC ENDORSES STEM CELL RESEARCH ENHANCEMENT ACT May 20, 2005 The Honorable Michael Castle The Honorable Diana L. DeGette Dear Representatives Castle and DeGette: The undersigned organizations dedicated to advocacy for people with cancer write to endorse H.R. 810, the Stem Cell Research Enhancement Act. Although the research agenda is still in its early phases, it is increasingly clear that embryonic stem cells offer tremendous potential to address human suffering from a wide range of diseases, including cancer. The Administration has already recognized
the theoretical advantages of stem cell research by permitting federal
funds to be used in research involving the limited number of stem cell
lines in existence at the time of that decision. Subsequently, however,
these existing stem cell lines have proven to be insufficient to explore
effectively the use of the technology in cancer and other serious and
life-threatening diseases. Federal policy governing embryonic stem cell
research needs to be modified to reflect advances in scientific knowledge
and the development of new stem cell lines. The Stem Cell Research Enhancement
Act will allow the use of additional stem cell lines and appropriate expansion
of the scope of stem cell research. The Honorable Michael Castle
Sincerely,
About CLC | What's New | Policy
Issues | Participants' Login Copyright
© 2001-2002 Cancer Leadership Council. All rights reserved. |